AML
Clinical trials for AML explained in plain language.
Never miss a new study
Get alerted when new AML trials appear
Sign up with your email to follow new studies for AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New weapon targets stubborn blood cancer cells
Disease control OngoingThis study is testing an experimental drug called vibecotamab for patients with two types of blood cancers (AML and MDS) that haven't responded fully to standard treatments or show lingering cancer cells. The trial aims to see if vibecotamab can eliminate these remaining cancer c…
Matched conditions: AML
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug combo aims to tame Tough-to-Treat blood cancer
Disease control OngoingThis study is testing a combination of three drugs—gemtuzumab ozogamicin, cytarabine, and gilteritinib—for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation and has come back or not responded to prior treatment. The main goals are to see if the …
Matched conditions: AML
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New attack plan for blood Cancer's comeback
Disease control OngoingThis study is testing a combination of two drugs (venetoclax and azacitidine) along with an infusion of immune cells from the original stem cell donor. It is for adults whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has come back after a stem cell transplant…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Scientists test new strategy to stop Leukemia's return
Disease control OngoingThis study is testing a new, personalized approach to treat acute myeloid leukemia (AML) when it starts to come back. Doctors will use genetic information from a patient's cancer to choose specific drug combinations, aiming to attack the disease early based on tiny traces of left…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC